Search results for "relation"

showing 10 items of 10542 documents

Impact of Biomedical and Biopsychosocial Training Sessions on the Attitudes, Beliefs and Recommendations of Health Care Providers about Low Back Pain…

2011

The beliefs and attitudes of health care providers may contribute to chronic low back pain (LBP) disability, influencing the recommendations that they provide to their patients. An excessively biomedical style of undergraduate training can increase negative beliefs and attitudes about LBP, whereas instruction following a biopsychosocial model could possibly lessen these negative beliefs in health care professionals. The objectives of this study were to determine the effectiveness of 2 brief educational modules with different orientations (biomedical or biopsychosocial) on changing the beliefs and attitudes of physical therapy students and the recommendations that they give to patients. The …

AdultMaleBiopsychosocial modelHealth Knowledge Attitudes PracticeInservice TrainingAdolescentAttitude of Health PersonnelPsychological interventionYoung AdultSocial supportContinuing medical educationHealth careBack painHumansMedicinehealth care economics and organizationsbusiness.industrySocial SupportProfessional-Patient RelationsFear-avoidance modelequipment and suppliesLow back painBiomechanical PhenomenaPhysical TherapistsAnesthesiology and Pain MedicinePsicobiologiaNeurologyFemaleNeurology (clinical)medicine.symptombusinessLow Back Painhuman activitiesClinical psychology
researchProduct

SYMPATHETIC NERVOUS SYSTEM AND BLOOD-PRESSURE CONTROL IN ESSENTIAL HYPERTENSION

1978

Abstract In normotensive subjects an inverse correlation was observed between an index of sympathetic nervous activity (the plasma-noradrenaline concentration during physical exercise) and reactivity to exogenous noradrenaline. This relationship was invariably disturbed in age-matched patients with essential hypertension. Multiple-regression analysis revealed a highly significant correlation between the combination of both factors and the height of mean arterial blood-pressure ( r =0·91). The findings suggest that sympathetic nervous activity and pressor response to noradrenaline together form an important determinant of the arterial blood-pressure level. An inverse relationship could be de…

AdultMaleBlood pressure controlmedicine.medical_specialtySympathetic nervous systemSympathetic Nervous SystemRestPhysical ExertionBlood PressurePhysical exerciseEssential hypertensionNorepinephrineInternal medicineReninHumansMedicineInverse correlationbusiness.industryAngiotensin IIGeneral MedicineMiddle Agedmedicine.diseaseAngiotensin IIHormonesmedicine.anatomical_structureEndocrinologyPressor responsePathophysiology of hypertensionHypertensionRegression AnalysisFemalebusinessThe Lancet
researchProduct

Fentanyl buccal tablets for breakthrough pain in highly tolerant cancer patients: preliminary data on the proportionality between breakthrough pain d…

2011

Abstract Context Cancer patients receiving high doses of opioids as background medication are challenging, and it would be useful clinically to know whether a rapid-onset opioid (ROO) for breakthrough cancer pain (BTcP) may be started at a dose proportional to the background opioid dose. Objectives The aim of this study was to assess the efficacy and safety of the fentanyl buccal tablet (FBT) in doses proportional to the opioid dose administered for background analgesia in a sample of patients with BTcP who were receiving high doses of opioids. Methods Twelve patients who were receiving opioids for background analgesia at doses equivalent to more than 500 mg of oral morphine and had adequat…

AdultMaleBreakthrough PainContext (language use)Settore MED/42 - Igiene Generale E ApplicataFentanylNeoplasmsHumansMedicineAdverse effectGeneral NursingAgedPain MeasurementDose-Response Relationship Drugbusiness.industryBreakthrough PainAdministration BuccalCancerclinical trialBuccal administrationMiddle Agedmedicine.diseaseFentanyl buccal tabletbreakthrough pain cancer patientAnalgesics OpioidFentanylTreatment OutcomeAnesthesiology and Pain MedicineOpioidAnesthesiaFemaleNeurology (clinical)businessCancer painmedicine.drug
researchProduct

Do asthmatic smokers benefit as much as non-smokers on budesonide/formoterol maintenance and reliever therapy? Results of an open label study

2012

SummaryBackgroundStudies with inhaled corticosteroids (ICS) in smoking asthmatics have mostly shown poorer treatment responses than in non-smoking asthmatics.MethodsEuroSMART, an open, randomised, 6-month study, compared budesonide/formoterol (Symbicort ® Turbuhaler®)hhNeither the Symbicort SMART posology nor the dry powder formulation, Turbuhaler, is currently approved in the US. maintenance and reliever therapy (Symbicort SMART®) at two maintenance doses of budesonide/formoterol (160/4.5 μg), 1 × 2 and 2 × 2, in patients with asthma who were symptomatic despite treatment with ICS ± long-acting β2-agonists. The 8424 randomised patients included 886 smokers (11%; aged <40 years or with a sm…

AdultMaleBudesonidePulmonary and Respiratory MedicineSymbicort SMARTmedicine.medical_specialtyPeak Expiratory Flow RatePropensity-matched controlsDrug Administration Schedulelaw.inventionACQ-5Budesonide/formoterol maintenance and reliever therapyPharmacotherapyRandomized controlled triallawFormoterol FumarateSurveys and QuestionnairesInternal medicineAdministration InhalationmedicineHumansAnti-Asthmatic AgentsDosingBudesonideAsthmaSmokersDose-Response Relationship Drugbusiness.industrySmokingmedicine.diseaseAsthmaBronchodilator Agentsrespiratory tract diseasesTreatment OutcomeBudesonide/formoterolEthanolaminesAnesthesiaDisease ProgressionDrug Therapy CombinationFemaleFormoterol FumarateFormoterolbusinessmedicine.drugRespiratory Medicine
researchProduct

How University Students With Reading Difficulties Are Supported in Achieving Their Goals

2015

We examine (a) what social ties university students with a history of reading difficulty (RD) report assisting them to achieve their goals, (b) outlets available for developing social ties, (c) resources mobilized within these relationships, and (d) the impact of social ties’ status on academic achievement. Participants were 107 university students with RD who were currently completing or had recently completed a university degree. Results showed that university students with RD named friends, parents, and significant others (e.g., boy/girlfriend, spouse) as social ties most often. Personal social ties were developed through social media networking sites and within close relationships, and…

AdultMaleCanadaHealth (social science)AdolescentUniversitiesAcademic achievementEducationDyslexiaSocial supportInterpersonal relationshipYoung AdultHumansSocial mediata516reading difficultiesStudentsta515Goal orientationMiddle AgedAchievementInterpersonal tiesgoal achievementGeneral Health Professionssocial capitalFemaleComputer-mediated communicationPsychologySocial psychologyGoalsSocial capitalJournal of Learning Disabilities
researchProduct

Somatostatin-receptor scintigraphy in Graves' disease: reproducibility and variance of orbital activity.

2000

Somatostatin-receptor (SSTR) scintigraphy using the single photon emission computed tomography (SPECT) technique allows the assessment of orbital inflammation in patients with Graves' disease. Previous studies showed differences in orbital octreotide uptake already 4 hr after injection. In this study, analysis of inter-/intra-observer variance and reproducibility in the evaluation of orbital SPECT images was performed. First, SPECT data of one representative female patient with clinically active Graves' ophthalmopathy (GO), obtained 4 hr after intravenous injection of 110 MBq 111In-pentetreotide and processed by filtered backprojection, were analyzed. Transverse SPECT images were reconstruc…

AdultMaleCancer ResearchGraves' diseaseSingle-photon emission computed tomographyScintigraphyCorrelationSpearman–Brown prediction formulamedicineHumansRadiology Nuclear Medicine and imagingAgedPharmacologyObserver VariationTomography Emission-Computed Single-PhotonReproducibilitymedicine.diagnostic_testbusiness.industryIndium RadioisotopesReproducibility of ResultsGeneral MedicineVariance (accounting)Middle Agedmedicine.diseaseGraves DiseaseOncologyFemaleTomographybusinessNuclear medicineSomatostatinOrbitCancer biotherapyradiopharmaceuticals
researchProduct

A phase I pharmacokinetic and pharmacodynamic study of dalotuzumab (MK-0646), an anti-insulin-like growth factor-1 receptor monoclonal antibody, in p…

2011

Abstract Purpose: Insulin-like growth factor-1 receptor (IGF-1R) mediates cellular processes in cancer and has been proposed as a therapeutic target. Dalotuzumab (MK-0646) is a humanized IgG1 monoclonal antibody that binds to IGF-1R preventing receptor activation. This study was designed to evaluate the safety and tolerability of dalotuzumab, determine the pharmacokinetic (PK) and pharmacodynamic (PD) profiles, and identify a recommended phase II dose. Experimental Design: Patients with tumors expressing IGF-1R protein were allocated to dose-escalating cohorts of three or more patients each and received intravenous dalotuzumab weekly, every 2 or 3 weeks. Plasma was collected for PK analysis…

AdultMaleCancer ResearchMaximum Tolerated Dosemedicine.medical_treatmentAntineoplastic AgentsPharmacologyAntibodies Monoclonal HumanizedDrug Administration ScheduleReceptor IGF Type 1Insulin-like growth factorPharmacokineticsNeoplasmsmedicineHumansAgedAged 80 and overDose-Response Relationship DrugDalotuzumabbusiness.industryCancerAntibodies MonoclonalMiddle Agedmedicine.diseaseOncologyTolerabilityPharmacodynamicsMonoclonalToxicityFemalebusinessClinical cancer research : an official journal of the American Association for Cancer Research
researchProduct

Escalating doses of paclitaxel and epirubicin in combination with cisplatin in advanced ovarian epithelial carcinoma: a phase I–II study

2003

Our objective was to identify a new active three-drug combination regimen consisting of paclitaxel (PTX), epirubicin (EPI) and cisplatin as first-line line chemotherapy for advanced ovarian carcinoma. A phase I study was carried out to evaluate the dose-limiting toxicity (DLT) and the maximally tolerated dose (MTD) of PXT and EPI in combination with a fixed dose of cisplatin every 4 weeks. Side-effects were recorded according to the NCI Common Toxicity Criteria. Patients were treated in cohorts of three with fixed-dose cisplatin 80 mg/m 2 and EPI 80 → 100 mg/ m 2 and PXT 100 → 160 mg/m 2 until DLT was reached. Once MTD was identified, a single-step phase II study was therefore carried out t…

AdultMaleCancer Researchmedicine.medical_specialtyAdolescentPaclitaxelmedicine.medical_treatmentUrologyPhases of clinical researchAntineoplastic AgentsPharmacologyAntineoplastic Combined Chemotherapy ProtocolsMucositisHumansMedicinePharmacology (medical)AgedEpirubicinNeoplasm StagingOvarian NeoplasmsPharmacologyCisplatinChemotherapyAntibiotics AntineoplasticDose-Response Relationship Drugbusiness.industryCarcinomaMiddle Agedmedicine.diseaseAntineoplastic Agents PhytogenicSurvival AnalysisRegimenOncologyToxicityAntiemeticsFemaleCisplatinbusinessFebrile neutropeniamedicine.drugEpirubicinAnti-Cancer Drugs
researchProduct

Phase I Pharmacokinetic and Pharmacodynamic Dose-Escalation Study of RG7160 (GA201), the First Glycoengineered Monoclonal Antibody Against the Epider…

2011

Purpose We conducted a phase I dose-escalation study to characterize the safety, efficacy, pharmacokinetic (PK), and pharmacodynamic properties of RG7160 (GA201), a humanized and glycoengineered immunoglobulin G1 anti–epidermal growth factor receptor (EGFR) monoclonal antibody with enhanced antibody-dependent cell-mediated cytotoxicity. Patients and Methods Seventy-five patients with advanced EGFR-positive solid tumors received RG7160 (50 to 1,400 mg) administered every week, every 2 weeks, or every 3 weeks. Dose escalation followed a three-plus-three trial design. Results No maximum-tolerated dose was reached for any dosing schedule. Common adverse events (AEs) included rash (80% of patien…

AdultMaleCancer Researchmedicine.medical_specialtyMaximum Tolerated DoseAntineoplastic AgentsPharmacologyAntibodies Monoclonal HumanizedGastroenterologyHypomagnesemiaCohort StudiesYoung AdultPharmacokineticsGrowth factor receptorNeoplasmsInternal medicineHumansMedicineDosingEpidermal growth factor receptorAdverse effectAgedGlycoproteinsAged 80 and overDose-Response Relationship Drugbiologybusiness.industryMiddle Agedmedicine.diseaseRashErbB ReceptorsOncologyPharmacodynamicsbiology.proteinFemalemedicine.symptombusinessJournal of Clinical Oncology
researchProduct

Final report of the efficacy and safety of gemtuzumab ozogamicin (Mylotarg) in patients with CD33-positive acute myeloid leukemia in first recurrence

2005

BACKGROUND In this study, the authors analyzed the efficacy and safety of gemtuzumab ozogamicin (GO) (Mylotarg®), an antibody-targeted chemotherapy for CD33-positive acute myeloid leukemia (AML). METHODS Patients with CD33-positive AML in first recurrence were entered in 3 open-label, single-arm, Phase II studies. Patients received monotherapy with GO 9 mg/m2 as a 2-hour intravenous infusion in 2 doses separated by 2 weeks. Patients were evaluated for remission, survival, and treatment-emergent adverse events. RESULTS Two hundred seventy-seven patients (median age, 61 yrs) were treated with GO, and 71 patients (26%) achieved remission, which was defined as ≤ 5% blasts in the bone marrow wit…

AdultMaleCancer Researchmedicine.medical_specialtyMyeloidMaximum Tolerated DoseGemtuzumab ozogamicinmedicine.medical_treatmentCD33Sialic Acid Binding Ig-like Lectin 3Antigens Differentiation MyelomonocyticHematopoietic stem cell transplantationNeutropeniaAntibodies Monoclonal HumanizedGastroenterologyRisk AssessmentSeverity of Illness IndexDrug Administration ScheduleClinical Trials Phase II as TopicAntigens CDRecurrenceInternal medicinemedicineHumansSingle-Blind MethodSurvival rateAgedAged 80 and overChemotherapyDose-Response Relationship Drugbusiness.industryAntibodies MonoclonalMiddle Agedmedicine.diseaseGemtuzumabSurgerySurvival RateLeukemiaLeukemia Myeloid Acutemedicine.anatomical_structureAminoglycosidesTreatment OutcomeOncologyEvaluation Studies as TopicFemalebusinessmedicine.drugFollow-Up StudiesCancer
researchProduct